NCT05405868View on ClinicalTrials.gov

Nicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

496

Participants

Timeline

Start Date

January 18, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

June 30, 2027

Conditions
Glaucoma, Open-Angle
Interventions
DRUG

Nicotinomide

Nicotinamide tablets (750mg)

DRUG

Matching placebo

Matching placebo

Trial Locations (10)

BT9 7AB

NOT_YET_RECRUITING

Belfast City Hospital, Belfast

CB2 OQQ

NOT_YET_RECRUITING

Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge

RH19 3DZ

RECRUITING

Queen Victoria Hospital NHS Foundation Trust, East Grinstead

L7 8XP

NOT_YET_RECRUITING

Royal Liverpool Hospital, Liverpool

EC1V 2PD

RECRUITING

Moorfields Eye Hospital NHS Foundation Trust, London

EN5 3DJ

NOT_YET_RECRUITING

Barnet Hospital, Royal Free London NHS Foundation Trust, London

SE5 9RS

RECRUITING

King's College Hospital NHS Foundation Trust, London

M13 9WL

NOT_YET_RECRUITING

Manchester Royal Eye Hospital, Manchester

NG7 2UH

NOT_YET_RECRUITING

Nottingham University Hospitals NHS Trust, Nottingham

PO6 3LY

RECRUITING

Queen Alexandra Hospital, Portsmouth

All Listed Sponsors
collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

University College, London

OTHER